talquetamab   Click here for help

GtoPdb Ligand ID: 12240

Synonyms: JNJ-64407564 | JNJ64407564 | talquetamab-tgvs | Talvey®
Approved drug
talquetamab is an approved drug (FDA & EMA (2023))
Compound class: Antibody
Comment: Talquetamab (JNJ-64407564) is a humanized, IgG4 bispecific monoclonal antibody that engages the orphan GPCR GPRC5D that's expressed on majority of malignant plasma cells from multiple myeloma (MM) patients and CD3ε on T cells [3]. It has amino acid substitutions in its Fc region to minimise binding to Fcγ receptors and antibody-directed effector functions. The peptide sequences for talquetamab's heavy and light chains are claimed in Janssen's patent US10562968B2 [1]. In preclinical studies talquetamab promoted immune killing of MM cells, including cells from patients with daratumumab-refractory disease [4].
No information available.
Summary of Clinical Use Click here for help
Talquetamab (JNJ-64407564) was progressed to phase 3 evaluations in patients with relapsed/refractory MM. Both the FDA and EMA granted approval in August 2023, for heavily pre-treated relapsed or refractory MM [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04586426 A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Phase 1 Interventional Janssen Research & Development, LLC
NCT04634552 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma Phase 2 Interventional Janssen Research & Development, LLC
NCT05455320 A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Phase 3 Interventional Janssen Research & Development, LLC
NCT05461209 A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma Phase 3 Interventional Janssen Research & Development, LLC
External links Click here for help
For extended ADME data see the following:

European Medicines Agency (EMA)